BioMedNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering

March 19, 2021 11:02:47

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering.

For more information about the company, visit

About Bio-Path Holdings Inc.

Bio-Path Holdings is a biotechnology company developing DNAbilize(R), a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path’s lead product candidate, prexigebersen (“BP1001,” targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by “BP1002,” targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork